Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FIXX NASDAQ:GMTX NASDAQ:MOR NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsGMTXGemini Therapeutics$89.94+21.0%$63.69$1.16▼$14.10$3.90B-0.12189,291 shs2.26 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AZYMEZymeworks$18.32-0.4%$15.88$9.03▼$19.50$1.38B1.51546,043 shs821,935 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%GMTXGemini Therapeutics0.00%+28.67%+47.95%+51.47%+77.89%MORMorphoSys0.00%0.00%0.00%0.00%0.00%ZYMEZymeworks-0.43%+1.16%+12.74%+27.93%+35.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsGMTXGemini Therapeutics$89.94+21.0%$63.69$1.16▼$14.10$3.90B-0.12189,291 shs2.26 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AZYMEZymeworks$18.32-0.4%$15.88$9.03▼$19.50$1.38B1.51546,043 shs821,935 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%GMTXGemini Therapeutics0.00%+28.67%+47.95%+51.47%+77.89%MORMorphoSys0.00%0.00%0.00%0.00%0.00%ZYMEZymeworks-0.43%+1.16%+12.74%+27.93%+35.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFIXXHomology Medicines 0.00N/AN/AN/AGMTXGemini Therapeutics 0.00N/AN/AN/AMORMorphoSys 0.00N/AN/AN/AZYMEZymeworks 3.00Buy$24.7535.10% UpsideCurrent Analyst Ratings BreakdownLatest FIXX, GMTX, MOR, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025ZYMEZymeworksJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $23.0010/14/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Buy$13.00 ➝ $26.0010/10/2025ZYMEZymeworksB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.008/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17ZYMEZymeworks$122.87M11.21N/AN/A$6.63 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%11/6/2025 (Estimated)Latest FIXX, GMTX, MOR, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025N/AZYMEZymeworks-$0.28N/AN/AN/A$33.69 millionN/A8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFIXXHomology MedicinesN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFIXXHomology MedicinesN/A7.257.25GMTXGemini TherapeuticsN/A71.4971.49MORMorphoSys4.981.381.38ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFIXXHomology Medicines31.32%GMTXGemini Therapeutics75.42%MORMorphoSys18.38%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipFIXXHomology Medicines16.10%GMTXGemini Therapeutics12.90%MORMorphoSys0.05%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableZYMEZymeworks46075.17 million67.56 millionOptionableFIXX, GMTX, MOR, and ZYME HeadlinesRecent News About These CompaniesZymeworks (NYSE:ZYME) Price Target Raised to $23.00October 19 at 2:57 AM | americanbankingnews.comJPMorgan ups Zymeworks target, places on ‘Positive Catalyst Watch’October 16, 2025 | msn.comWall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to TradeOctober 16, 2025 | zacks.comJPMorgan Chase & Co. Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock PriceOctober 16, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Zymeworks Q3 Earnings?October 16, 2025 | marketbeat.comZymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025October 16, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Zymeworks (ZYME)October 14, 2025 | msn.comZymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?October 14, 2025 | zacks.comZymeworks (NYSE:ZYME) Shares Gap Up - Here's WhyOctober 14, 2025 | marketbeat.comZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ConferenceOctober 13, 2025 | tmcnet.comZymeworks Inc.: Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ...October 13, 2025 | finanznachrichten.deZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International ConferenceOctober 13, 2025 | globenewswire.comZymeworks (NYSE:ZYME) Stock Price Up 7.2% - Here's What HappenedOctober 11, 2025 | marketbeat.comEquities Analysts Set Expectations for Zymeworks Q3 EarningsOctober 11, 2025 | americanbankingnews.comLifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME)October 10, 2025 | marketbeat.comZymeworks appoints Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | msn.comInMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsOctober 9, 2025 | newsfilecorp.comNZymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | globenewswire.comWhy Analysts See the Zymeworks Story Evolving After Key Pipeline and Market MovesOctober 8, 2025 | finance.yahoo.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalOctober 8, 2025 | marketbeat.comPlatinum Investment Management Ltd. Decreases Stake in Zymeworks Inc. $ZYMEOctober 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Why Amazon’s Latest Upgrade Might Be Its Most Important YetBy Sam Quirke | October 1, 2025Airlines Are Taking Off, With More Gains Left to Price InBy Gabriel Osorio-Mazilli | September 25, 2025Lithium Americas Stock Exploded Last Week—Here’s WhyBy Jordan Chussler | October 1, 2025Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300By Sam Quirke | September 29, 2025FIXX, GMTX, MOR, and ZYME Company DescriptionsHomology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Gemini Therapeutics NASDAQ:GMTX$89.94 +15.58 (+20.95%) As of 10/17/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 10/17/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Zymeworks NYSE:ZYME$18.32 -0.08 (-0.43%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$18.94 +0.62 (+3.39%) As of 10/20/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
